60 Pages Posted: 25 May 2017 Last revised: 26 Jul 2017
Date Written: July 25, 2017
We apply machine-learning techniques to predict drug approvals and phase transitions using drug-development and clinical-trial data from 2003 to 2015 involving several thousand drug-indication pairs with over 140 features across 15 disease groups. Imputation methods are used to deal with missing data, allowing us to fully exploit the entire dataset, the largest of its kind. We achieve predictive measures of 0.74, 0.78, and 0.81 AUC for predicting transitions from phase 2 to phase 3, phase 2 to approval, and phase 3 to approval, respectively. Using five-year rolling windows, we document an increasing trend in the predictive power of these models, a consequence of improving data quality and quantity. The most important features for predicting success are trial outcomes, trial status, trial accrual rates, duration, prior approval for another indication, and sponsor track records. We provide estimates of the probability of success for all drugs in the current pipeline.
Keywords: biotech; pharmaceuticals; risk management; machine learning
JEL Classification: I10, I11, G11, G32, C55, C13
Suggested Citation: Suggested Citation
Lo, Andrew W. and Siah, Kien Wei and Wong, Chi Heem, Machine-Learning Models for Predicting Drug Approvals and Clinical-Phase Transitions (July 25, 2017). Available at SSRN: https://ssrn.com/abstract=2973611